Home » Topics » BioWorld Science

BioWorld Science
RSS

Eli Lilly presents AOC3 inhibitors

Sep. 7, 2018

Phase IIa study of Yeliva for cholangiocarcinoma advances to second stage

Sep. 7, 2018

FDA approves Tiglutik oral suspension for the treatment of ALS

Sep. 7, 2018

Chinese researchers disclose Abeta aggregation inhibitors

Sep. 7, 2018

Xenon Pharmaceuticals to develop ezogabine for KCNQ2 epileptic encephalopathy

Sep. 7, 2018

A*STAR identifies new SMYD3 inhibitors for cancer

Sep. 7, 2018

Torrent Pharmaceuticals patents compounds for asthma and COPD

Sep. 7, 2018

Researchers identify FHOD3 as a novel disease-causing gene in hypertrophic cardiomyopathy

Sep. 7, 2018

Combining ACE2 and BNP biomarkers improves risk stratification in patients with aortic stenosis

Sep. 7, 2018

HAS2 gene linked to the pathogenesis of lower extremity varicose veins

Sep. 7, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...